Windtree Therapeutics Appoints Leanne Kelly to Board of Directors and Audit Committee

Windtree Therapeutics, Inc. (NASDAQ: WINT) made a significant announcement following a recent Board of Directors meeting that took place on January 8, 2025. The company revealed that the Board has sanctioned an increase in the number of directors to five and has named Leanne Kelly as a director and member, as well as chair, of the Audit Committee, effective immediately.

Leanne Kelly, aged 47, brings a wealth of experience to her new role at Windtree Therapeutics. She currently holds the position of Chief Financial Officer at GRI Bio, Inc., a biotechnology firm focused on developing cell modulators for treating inflammatory, fibrotic, and autoimmune diseases, a role she has held since April 2023. Kelly has garnered over two decades of experience leading both private and publicly traded companies across various sectors, including life sciences, technology, and e-Commerce. Her professional background includes serving as the Chief Financial Officer of Vallon Pharmaceuticals, Inc. until its merger with GRI Bio, Inc. from May 2021 to April 2023, and as the Controller and Executive Director of Global Financial Reporting at OptiNose, Inc. from 2016 to 2021.

Kelly commenced her career as an auditor at KPMG LLP and has since held key financial positions at several prominent companies, including Flower Orthopedics, Iroko Pharmaceuticals, LLC, and Genaera Corporation. She holds a B.Sc. in Business Economics with a concentration in Accounting from Lehigh University and is a licensed CPA (inactive status) in Pennsylvania.

The appointment of Leanne Kelly comes at a critical juncture for Windtree Therapeutics. The Company recently received a notification from the Nasdaq Listing Qualification Department on December 4, 2024, indicating non-compliance with Nasdaq’s independent director and auditor committee requirements stipulated in Listing Rule 5605. However, the Company expects that Kelly’s appointment as an independent director and member of the Audit Committee will rectify this non-compliance issue.

In compliance with reporting obligations, Windtree Therapeutics has filed a press release about these developments dated January 13, 2025. Additionally, the Company has submitted the necessary documents, including a Cover Page Interactive Data File, as required in Exhibit 99.1 and Exhibit 104, respectively.

As of the submission of this report, Windtree Therapeutics has duly affirmed the appointment of Leanne Kelly as a director and member of the Audit Committee, reinforcing its commitment to governance and regulatory compliance.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Windtree Therapeutics’s 8K filing here.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.